LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Lista de Ações・MannKind Corp

MannKind Corp

Fechado

SetorSaúde

3.52 1.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.37

Máximo

3.48

Indicadores-chave
By Trading Economics
Rendimento	-671K -17M
Vendas	-22M 90M
P/E Médio do Setor	140.5 49.888
EPS	-0.02
Margem de lucro	-18.431
Funcionários	591
EBITDA	5.9M 3.4M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+139.71% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	223M 1.1B
Abertura anterior	2.08
Fecho anterior	3.52

Sentimento de Notícias

By Acuity

17%

83%

34 / 344 Ranking em Healthcare

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de jun. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 de jun. de 2026, 15:41 UTC

Grandes Movimentos do Mercado

American Battery Shares Jump on Energy Department Victory

8 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 de jun. de 2026, 23:37 UTC

Conversa de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 de jun. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Agrees to Buy m3ter

8 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

8 de jun. de 2026, 19:22 UTC

Conversa de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 de jun. de 2026, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 de jun. de 2026, 18:17 UTC

Conversa de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 de jun. de 2026, 17:32 UTC

Conversa de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de jun. de 2026, 16:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 de jun. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 de jun. de 2026, 16:40 UTC

Conversa de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 16:31 UTC

Conversa de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 de jun. de 2026, 16:27 UTC

Conversa de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de jun. de 2026, 16:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Bought Stake From Lorca

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Acquires 100% Ownership of MasOrange

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 15:55 UTC

Conversa de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 de jun. de 2026, 15:41 UTC

Conversa de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

139.71% parte superior

Previsão para 12 meses

Média 8.15 USD 139.71%

Máximo 11 USD

Mínimo 4.75 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

34 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.